Crinetics Pharmaceuticals (CRNX) Tops Q1 EPS by 5c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q1 EPS of ($1.23), $0.05 better than the analyst estimate of ($1.28). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $8.51 million.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• BofA Securities Upgrades Etsy (ETSY) to Buy, 'Still Room to Run'
• William Blair Starts Surrozen Inc. (SRZN) at Outperform